Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer

Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC).

(2017) J. Crown et al.   JOURNAL OF CLINICAL ONCOLOGY

Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC).

(2017) J. Bergh et al.   JOURNAL OF CLINICAL ONCOLOGY

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2011) Adam M. Brufsky et al.   JOURNAL OF CLINICAL ONCOLOGY

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

(2011) Nicholas J. Robert et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

(2010) Carlos H. Barrios et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2010) David W. Miles et al.   JOURNAL OF CLINICAL ONCOLOGY

Disease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials

(2010) David Miles et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer

(2009) Giulia Bianchi et al.   ANTI-CANCER DRUGS

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

(2009) John M.L. Ebos et al.   CANCER CELL

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

Colorectal Hepatic Metastases: Adjuvant Chemotherapy and Survival

(2009) David J. Gallagher et al.   JOURNAL OF CLINICAL ONCOLOGY

Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathways

(2008) Vivek Roy et al.   BREAST CANCER RESEARCH AND TREATMENT

Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense?

(2008) Lori E. Dodd et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Sorafenib in Patients With Metastatic Breast Cancer Previously Exposed to Anthracyclines or Taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336

(2008) Alvaro Moreno-Aspitia et al.   JOURNAL OF CLINICAL ONCOLOGY

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

(2008) Scott M. Wilhelm et al.   MOLECULAR CANCER THERAPEUTICS

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selected Combination Therapy with Sorafenib: A Review of Clinical Data and Perspectives in Advanced Solid Tumors

(2008) L. Dal Lago et al.   ONCOLOGIST

Effective oral chemotherapy for breast cancer: pillars of strength

(2007) M. Findlay et al.   ANNALS OF ONCOLOGY